Regeneron Pharmaceuticals Inc (REGN) Now Covered by CIBC

Equities research analysts at CIBC began coverage on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in a report issued on Friday. The firm set a “market perform” rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the stock. Oppenheimer Holdings Inc. began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, March 16th. They set a “hold” rating on the stock. Vetr raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 price objective on the stock in a report on Wednesday, March 15th. Piper Jaffray Companies set a $446.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 8th. Goldman Sachs Group Inc downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Thursday, February 16th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $410.00 price objective (down from $420.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, February 16th. Fourteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $434.97.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 382.02 on Friday. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $452.96. The company has a market capitalization of $40.29 billion, a price-to-earnings ratio of 49.62 and a beta of 1.44. The firm has a 50-day moving average of $371.86 and a 200 day moving average of $379.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.01. The business had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.83 earnings per share. Analysts expect that Regeneron Pharmaceuticals will post $12.95 EPS for the current fiscal year.

Your IP Address:

In related news, major shareholder Sanofi acquired 87,298 shares of the firm’s stock in a transaction that occurred on Wednesday, January 11th. The shares were bought at an average cost of $369.71 per share, for a total transaction of $32,274,943.58. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the period. IFP Advisors Inc boosted its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares during the period. Live Your Vision LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at $157,000. Global X Management Co. LLC boosted its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the period. Finally, Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $160,000. Institutional investors own 68.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply